Synthesis and antifungal activity in vitro of isoniazid Derivatives against histoplasma capsulatum var. Capsulatum

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2504-2511

  De Aguiar Cordeiro, Rossana ^a   De Farias Marques, Francisca Jakelyne ^a   De Aguiar Cordeiro, Rebecca ^a   Da Silva, Marcos Reinaldo ^a   Malaquias, Angela Donato Maia ^a   De Melo, Charlline Vládia Silva ^a   Mafezoli, Jair ^a   De Oliveira, Maria Da Conceição Ferreira ^a   Brilhante, Raimunda Sâmia Nogueira ^a   Rocha, Marcos Fábio Gadelha ^a,b   De Jesus Pinheiro Gomes Bandeira, Tereza ^a,c   Sidrima, José Júlio Costa ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b STATE UNIVERSITY OF CEARÁ   (Brazil)

^c CENTRO UNIVERSITÁRIO UNICHRISTUS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ERGOSTEROL; ISONIAZID DERIVATIVE; ITRACONAZOLE; N'(1 M TOLYLETHYLIDENE)ISONICOTINOHYDRAZIDE; N'(1 PHENYLETHYLIDENE)ISONICOTINOHYDRAZIDE; N'(1,2 DIPHENYLETHYLIDENE) 2 ISONICOTINOHYDRAZIDE; N'[1 (2 METHOXYPHENYL)ETHYLIDENE]ISONICOTINOHYDRAZIDE; N'[1 (2 NITROPHENYL)ETHYLIDENE]ISONICOTINOHYDRAZIDE; N'[1 (3 METHOXYPHENYL)ETHYLIDENE]ISONICOTINOHYDRAZIDE; N'[1 (4 BROMOPHENYL)ETHYLIDENE]ISONICOTINOHYDRAZIDE; N'[1 (4 CHLOROPHENYL)ETHYLIDENE]ISONICOTINOHYDRAZIDE; N'[1 (4 NITROPHENYL)ETHYLIDENE]ISONICOTINOHYDRAZIDE; UNCLASSIFIED DRUG; ISONIAZID;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; BROTH DILUTION; CELL MEMBRANE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; EVALUATION STUDY; FUNGAL CELL; HISTOPLASMA CAPSULATUM; IN VITRO STUDY; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; HISTOPLASMA; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; HISTOPLASMA; ISONIAZID; MICROBIAL SENSITIVITY TESTS;

EID: 84898618435     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01654-13     Document Type: Article

References (36)

1. Wheat LJ, Connolly P, Smedema M, Durkin M, Brizendine E, Mann P, Patel R, McNicholas PM, Goldman M. 2006. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J. Antimicrob. Chemother. 57:1235-1239. http://dx.doi.org/10.1093/jac/dkl133.
2. Yamazaki T, Inagaki Y, Fujii T, Ohwada J, Tsukazaki M, Umeda I, Kobayashi K, Shimma N, Page MG, Arisawa M. 2010. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int. J. Antimicrob. Agents. 36:324-331. http://dx.doi.org/10.1016/j. ijantimicag.2010.06.003.
3. Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R, AIDS Clinical Trials Group and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. 2001. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin. Infect. Dis. 33:1910-1913. http://dx.doi.org/10.1086/323781.
4. Brilhante RS, Fechine MA, Mesquita JR, Cordeiro RA, Rocha MF, Monteiro AJ, Lima RA, Caetano ÉP, Pereira JF, Castelo-Branco DS, Camargo ZP, Sidrim JJ. 2012. Histoplasmosis in HIV-positive patients in Ceará, Brazil: clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates. Trans. R. Soc. Trop. Med. Hyg. 106:484-488. http://dx.doi.org/10.1016/j.trstmh.2012.05.003.
5. Wheat LJ, Connolly P, Smedema M, Rogers PD. 2009. Antifungal drug resistance in histoplasmosis, p 987-992. In Wheat LJ, DL Mayers (ed), Antimicrobial drug resistance: clinical and epidemiological aspects. Humana Press, New York, NY.
6. Varma A, Kwon-Chung KJ. 2010. Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob. Agents Chemother. 54:2303-2311. http://dx.doi.org/10. 1128/AAC.00153-10.
7. Kriesel JD, Sutton DA, Schulman S, Fothergill AW, Rinaldi MG. 2008. Persistent pulmonary infection with an azole-resistant Coccidioides species. Med. Mycol. 46:607-610. http://dx.doi.org/10.1080/1369378080214 0923.
8. Afeltra J, Verweij PE. 2003. Antifungal activity of nonantifungal drugs. Eur. J. Clin. Microbiol. Infect. Dis. 22:397-407. http://dx.doi.org/10.1007/ s10096-003-0947-x.
9. Ali I, Wani WA, Khan A, Haque A, Ahmad A, Saleem K, Manzoor N. 2012. Synthesis and synergistic antifungal activities of a pyrazoline based ligand and its copper(II) and nickel(II) complexes with conventional antifungals. Microb. Pathog. 53:66-73. http://dx.doi.org/10.1016/j.micpath.2012.04.005.
10. de Aguiar Cordeiro RA, de Farias Marques FJ, Brilhante RSN, de Castro e Silva KR, Mourão CI, Caetano ÉP, Fechine MAB, Ribeiro JF, Castelo-Branco DDSCM, Chaves de Lima RA, Mesquita JRL, Monteiro AJ, Rocha FAC, Rocha MFG, Sidrim JJC. 2011. Synergistic effect of antituberculosis drugs and azoles in vitro against Histoplasma capsulatum var. capsulatum. J. Antimicrob. Chemother. 55:4482-4484. http://dx.doi.org/10.1128/AAC.01471-10.
11. Ramos-e-Silva M, Lima CM, Schechtman RC, Trope BM, Carneiro S. 2012. Systemic mycoses in immunodepressed patients (AIDS). Clin. Dermatol. 30: 616-627. http://dx.doi.org/10.1016/j.clindermatol.2012.01.008.
12. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE, U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. 2002. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 137:105-109. http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00008.
13. Hills-Nieminen C, Hughes CA, Houston S, Shafran SD. 2009. Drugdrug interaction between itraconazole and the protease inhibitor lopinavir/ ritonavir. Ann. Pharmacother. 43:2117-2120. http://dx.doi.org/10.1345/aph.1M393.
14. de Aguiar Cordeiro R, Brilhante RS, Rocha MF, Fechine MA, Camargo ZP, Sidrim JJ. 2006. In vitro inhibitory effect of antituberculosis drugs on clinical and environmental strains of Coccidioides posadasii. J. Antimicrob. Chemother. 58:575-579. http://dx.doi.org/10.1093/jac/dkl290.
15. Ilić BS, Konstantinović SS, Savić DS, Veljković VB, Gojgić-Cvijović G. 2010. The impact of Schiff bases on antibiotic production by Streptomyces hygroscopicus. Med. Chem. Res. 19:690-697. http://dx.doi.org/10.1007/s00044-009-9223-7.
16. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M. 2003. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. 47:1376-1381. http://dx.doi.org/10.1128/AAC.47.4.1376-1381.2003.
17. Brilhante RSN, Fechine MAB, de Aguiar Cordeiro R, Rocha MFG, Ribeiro JF, Monteiro AJ, Chaves de Lima RA, Mesquita JRL, Pires de Camargo Z, Sidrim JJC. 2010. In vitro effect of sulfamethoxazoletrimethoprim against Histoplasma capsulatum var. capsulatum. Antimicrob. Agents Chemother. 54:3978-3979. http://dx.doi.org/10.1128/AAC.00793-10.
18. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715. http://dx.doi.org/10.1128/AAC.48.3.693-715.2004.
20. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. http://dx.doi.org/10.1093/jac/ dkg301.
21. Moran GP, Pinjon E, Coleman DC, Sullivan DJ. 2007. Analysis of drug resistance in pathogenic fungi, p 93-113. In Kavanagh K (ed), Medical mycology: cellular and molecular techniques. John Wiley & Sons, Ltd., Hoboken, NJ.
22. Devi KP, Nisha SA, Sakthivel R, Pandian SK. 2010. Eugenol (an essential oil of clove) acts as an antibacterial agent against Salmonella Typhi by disrupting the cellular membrane. J. Ethnopharmacol. 130:107-115. http://dx.doi.org/10.1016/j.jep.2010.04.025.
23. Pitangui NS, Sardi JC, Silva JF, Benaducci T, Moraes da Silva RA, Rodríguez-Arellanes G, Taylor ML, Mendes-Giannini MJ, Fusco-Almeida AM. 2012. Adhesion of Histoplasma capsulatum to pneumocytes and biofilm formation on an abiotic surface. Biofouling 28:711-718. http://dx.doi.org/10.1080/08927014. 2012.703659.
24. Shinde RB, Chauhan NM, Raut JS, Karuppayil SM. 2012. Sensitization of Candida albicans biofilms to various antifungal drugs by cyclosporine A. Ann. Clin. Microbiol. Antimicrob. 11:1-7. http://dx.doi.org/10.1186/1476-0711-11-1.
25. de Aguiar Cordeiro R, Mourão CI, Rocha MF, de Farias Marques FJ, Teixeira CE, de Oliveira Miranda DF, Neto LV, Brilhante RS, de Jesus Pinheiro Gomes Bandeira T, Sidrim JJ. 2012. Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 32:557-564. http://dx.doi.org/10.1007/s10096-012-1774-8.
26. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
27. Judge V, Narasimhan B, Ahuja M, Sriram D, Yogeeswari P, De Clercq E, Pannecouque C, Balzarini J. 2012. Synthesis, antimycobacterial, antiviral, antimicrobial activities, and QSAR studies of isonicotinic acid-1-(substituted phenyl)-ethylidene/cycloheptylidene hydrazides. Med. Chem. Res. 21:1935-1952. http://dx.doi.org/10.1007/s00044-011-9705-2.
28. Rollas S, Küçükgüzel ŞG. 2007. Biological activities of hydrazone derivatives. Molecules 12:1910-1939. http://dx.doi.org/10.3390/12081910.
29. Reis SLGB, Almeida VM, de Almeida GC, de Boaviagem KMM, Mendes CCDB, Faria AR, de Góes AJ, da Silva Magalhães LR, da Silva TG. 2011. Síntese e avaliação preliminar da atividade antinociceptiva de novas isoxazolilaril-hidrazonas. Quim. Nova. 34:76-81. (In Portuguese.) http://dx.doi.org/10.1590/S0100-40422011000100015.
30. Todeschini AR, de Miranda ALP, da Silva KCM, Parrini SC, Barreiro EJ. 1998. Synthesis and evaluation of analgesic, antiinflammatory and antiplatelet properties of new 2-pyridylarylhydrazone derivatives. Eur. J. Med. Chem. 33:189-199. http://dx.doi.org/10.1016/S0223-5234(98) 80008-1.
31. Visbal G, San-Blas G, Maldonado A, Álvarez-Aulara Á, Capparelli MV, Murgich J. 2011. Synthesis, in vitro antifungal activity and mechanism of action of four sterol hydrazone analogues against the dimorphic fungus Paracoccidioides brasiliensis. Steroids 76:1069-1081. http://dx.doi.org/10.1016/j.steroids.2011.04.012.
32. Carson CF, Mee BJ, Riley TV. 2002. Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrob. Agents Chemother. 46:1914-1920. http://dx.doi.org/10.1128/AAC.46.6.1914-1920. 2002.
33. Kuhn DM, Balkis M, Chandra J, Mukherjee PK, Ghannoum MA. 2003. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J. Clin. Microbiol. 41:506-508. http://dx.doi.org/10.1128/JCM.41.1.506-508.2003.
34. Nett JE, Cain MT, Crawford K, Andes DR. 2011. Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. J. Clin. Microbiol. 49:1426-1433. http://dx.doi.org/10. 1128/JCM.02273-10.
35. Peigne V, Dromer F, Elie C, Lidove O, Lortholary O, French Mycosis Study Group. 2011. Imported acquired immunodeficiency syndromerelated histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras. Am. J. Trop. Med. Hyg. 85:934-941. http://dx.doi.org/10.4269/ajtmh.2011.11-0224.
36. Wheat LJ. 2004. Therapy for severe histoplasmosis: what's best? Clin. Infect. Dis. 38:461-463. http://dx.doi.org/10.1086/381033.